在糖尿病病中探索结合费内伦和埃克萨纳提德治疗的脏保护作用
Ayse Kocak1, Elif Aydin2, Meliha Koldemir Gündüz3
1Kütahya Health Sciences University, Faculty of Medicine, Medical Biochemistry Department, Kütahya, Turkey.
International immunopharmacology
|October 16, 2025
概括
结合菲内伦和埃克萨纳提德可为糖尿病病 (DN) 提供显著的保护作用. 这种组合疗法有效地减少了炎症和氧化应激,增强了功能,超过了单独的治疗方法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DN) 是2型糖尿病 (T2DM) 的严重并发症,导致末期病.
- 氧化应激,炎症和异常信号通路是DN病变发生的关键驱动因素.
- 费内伦和埃克萨纳提德具有已知的保护性,抗炎性和抗氧化性.
研究的目的:
- 为了研究结合费内伦和埃克萨纳提德治疗的协同性脏保护作用.
- 评估这种组合对糖尿病病鼠模型功能,组织学,炎症和氧化应激的影响.
主要方法:
- 在Wistar大鼠中,斯特佐托 (STZ) 诱导糖尿病,分为对照组,糖尿病组和治疗组 (finerenone,exenatide或组合).
- 通过血清尿素,肌素和估计的淋巴细胞过率 (eGFR) 评估功能.
- 进行了组织学分析 (H&E,PAS,马森三染色体) 并测量了炎症基因/蛋白质表达和氧化应激标志物.
主要成果:
- 由STZ诱导的糖尿病导致严重的损伤,炎症和氧化应激.
- 费内伦和埃克萨纳提德单一疗法都改善了结局.
- 组合疗法在减少球损伤,炎症和氧化应激方面表现出卓越的疗效,同时促进NRF2激活.
结论:
- 结合的芬瑞和埃克萨纳提德在糖尿病脏病中表现出强大的脏保护作用.
- 这种组合通过调节关键信号通路 (NF-κB,PI3K/Akt/mTOR,NRF2) 来减轻炎症和氧化损伤.
- 这些发现支持结合费内伦和埃克萨纳提德用于治疗糖尿病病的治疗潜力.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
916
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
24.3K
相关概念视频
01:15Renal Drug Excretion: Overview
646
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
646
01:22Heart Failure Drugs: Diuretics
796
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
796
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
01:11Renal Failure: Dose Adjustments
434
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
434
01:28Renal Drug Excretion: Tubular Secretion
770
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
770
01:02Renal Drug Excretion: Glomerular Filtration
1.2K
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
1.2K